Krystal Biotech (KRYS) Announces Positive Topline Results from GEM-3 Pivotal Trial of VYJUVEK in Patients with Dystrophic Epidermolysis Bullosa
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/26/2026
- Wall Street closes lower to end rocky week
- Meta's capital-raising plans expose a major weakness in the AI boom
- Oil prices jump $3 on Houthi attacks, oil spill, highest settlement since April
- BofA flags further downside risk for stocks, yields and dollar
- SpaceX cell-site ambitions lift tower stocks and weigh on carriers
| (NASDAQ: KRYS) | Delayed: 311.50 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $311.50 | 52 Week High | $ | |||
| Open | $311.50 | 52 Week Low | $ | |||
| Day High | $311.50 | P/E | N/A | |||
| Day Low | $311.50 | EPS | $ | |||
| Volume | 5 | |||||
